dacarbazine has been researched along with cep 8983 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ator, M; Chang, H; Deibold, J; Grobelny, J; Hudkins, R; Husten, J; McGann, N; Miknyoczki, S; Parchment, R; Pritchard, S; Ruggeri, B; Worrell, C; Zulli, A | 1 |
Aissat-Daudigny, L; Brown, PD; Cambois, A; Campone, M; Moachon, G; Plummer, R; Stephens, P | 1 |
1 trial(s) available for dacarbazine and cep 8983
Article | Year |
---|---|
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalimides; Poly(ADP-ribose) Polymerase Inhibitors; Prodrugs; Prognosis; Temozolomide; Tissue Distribution; Young Adult | 2014 |
1 other study(ies) available for dacarbazine and cep 8983
Article | Year |
---|---|
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carbazoles; Cell Death; Cell Line, Tumor; Cell Proliferation; Comet Assay; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; G2 Phase; Humans; Irinotecan; Mice; Phthalimides; Poly Adenosine Diphosphate Ribose; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2007 |